BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36475520)

  • 1. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation.
    Yerushalmi Y; Shem-Tov N; Danylesko I; Canaani J; Avigdor A; Yerushalmi R; Nagler A; Shimoni A
    Haematologica; 2023 Jul; 108(7):1782-1792. PubMed ID: 36475520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.
    Christopeit M; Kuss O; Finke J; Bacher U; Beelen DW; Bornhäuser M; Schwerdtfeger R; Bethge WA; Basara N; Gramatzki M; Tischer J; Kolb HJ; Uharek L; Meyer RG; Bunjes D; Scheid C; Martin H; Niederwieser D; Kröger N; Bertz H; Schrezenmeier H; Schmid C
    J Clin Oncol; 2013 Sep; 31(26):3259-71. PubMed ID: 23918951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
    Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    Choi Y; Choi EJ; Lee JH; Lee KH; Jo JC; Park HS; Lee YJ; Seol M; Lee YS; Kang YA; Jeon M; Lee JH
    Clin Transplant; 2021 Mar; 35(3):e14199. PubMed ID: 33349948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.
    Tomonari A; Iseki T; Ooi J; Nagayama H; Sato H; Takahashi T; Ito K; Nagamura F; Uchimaru K; Takahashi S; Shirafuji N; Tojo A; Tani K; Asano S
    Int J Hematol; 2002 Apr; 75(3):318-23. PubMed ID: 11999364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
    Han T; Sun Y; Liu Y; Yan C; Wang Y; Xu L; Liu K; Huang X; Zhang X
    Front Med; 2021 Oct; 15(5):728-739. PubMed ID: 34279770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Swoboda R; Kulagin A; Velardi A; Sanz J; Labussière-Wallet H; Potter V; Kuball J; Sica S; Parovichnikova E; Bethge W; Maillard N; Platzbecker U; Stölzel F; Ciceri F; Mohty M
    Bone Marrow Transplant; 2023 Sep; 58(9):1008-1016. PubMed ID: 37253804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.
    Gao L; Yang L; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu D; Wu X
    Stem Cell Res Ther; 2024 Jan; 15(1):24. PubMed ID: 38282037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Decroocq J; Itzykson R; Vigouroux S; Michallet M; Yakoub-Agha I; Huynh A; Beckerich F; Suarez F; Chevallier P; Nguyen-Quoc S; Ledoux MP; Clement L; Hicheri Y; Guillerm G; Cornillon J; Contentin N; Carre M; Maillard N; Mercier M; Mohty M; Beguin Y; Bourhis JH; Charbonnier A; Dauriac C; Bay JO; Blaise D; Deconinck E; Jubert C; Raus N; Peffault de Latour R; Dhedin N
    Am J Hematol; 2018 Mar; 93(3):416-423. PubMed ID: 29226497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
    Tsai SB; Rhodes J; Liu H; Shore T; Bishop M; Cushing MM; Gergis U; Godley L; Kline J; Larson RA; Mayer S; Odenike O; Stock W; Wickrema A; van Besien K; Artz AS
    Biol Blood Marrow Transplant; 2018 May; 24(5):997-1004. PubMed ID: 29288821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
    Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
    [No Abstract]   [Full Text] [Related]  

  • 17. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
    Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
    Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
    Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
    Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
    Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.